Literature DB >> 29138878

Higher Cost of Hospitalizations for Non-cardiac Diagnoses in Adults with Congenital Heart Disease.

Michael D Seckeler1, Ian D Thomas2, Jennifer Andrews3, Omar Meziab4, Tabitha Moe5, Elissa Heller6, Scott E Klewer3.   

Abstract

Adults with congenital heart disease (CHD) are a rapidly increasing population and their impact on healthcare resources is not fully understood. The purpose of this study was to describe the costs of hospitalizations for non-cardiac disease for adults with CHD. We conducted a retrospective review of hospital discharge data from the University HealthSystem Consortium Clinical Data Base/Resource Manager from January 2011 through December 2013. Patients were ≥ 18 years old at admission with any ICD-9 code for moderate or high severity CHD; cardiac surgical admissions were excluded. The comparison group consisted of patients ≥ 18 years old with no ICD-9 codes for any severity CHD. There were 9,169,700 non-CHD, 28,224 moderate CHD, and 3045 high severity CHD hospital admissions. Total length of stay was longer for acute kidney injury, depressive disorder, esophageal reflux, and obstructive sleep apnea for any severity CHD; ICU admission rates were higher for all diagnoses with any severity CHD. Mean observed direct costs were higher for all diagnoses for moderate CHD and all diagnoses except dehydration, type 2 diabetes, obesity, and obstructive sleep apnea for high severity CHD. This review identified significantly increased hospitalization costs for adults with moderate and high severity CHD who are admitted for non-cardiac medical conditions not associated with concomitant cardiac surgical procedures. Admissions with CHD diagnoses had higher ICU admission rates, longer lengths of stay, and higher mortality for most non-cardiac admission diagnoses. These data will add to our understanding of the economic impact of adults with CHD.

Entities:  

Keywords:  Administrative dataset; Cost comparison; Fontan procedure; Heart defects, congenital; Hospitalizations; Tetralogy of fallot; Transposition of the great arteries

Mesh:

Year:  2017        PMID: 29138878     DOI: 10.1007/s00246-017-1770-y

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  17 in total

1.  Task force 1: the changing profile of congenital heart disease in adult life.

Authors:  C A Warnes; R Liberthson; G K Danielson; A Dore; L Harris; J I Hoffman; J Somerville; R G Williams; G D Webb
Journal:  J Am Coll Cardiol       Date:  2001-04       Impact factor: 24.094

2.  Mortality in adult congenital heart disease: are national registries reliable for cause of death?

Authors:  A Carla Zomer; Cuno S P M Uiterwaal; Enno T van der Velde; Jan G P Tijssen; Edwin C M Mariman; Carianne L Verheugt; Ilonca Vaartjes; Petronella G Pieper; Folkert J Meijboom; Diederick E Grobbee; Barbara J M Mulder
Journal:  Int J Cardiol       Date:  2010-08-01       Impact factor: 4.164

3.  Use of an administrative database to determine clinical management and outcomes in congenital heart disease.

Authors:  Howard P Gutgesell; Diane G Hillman; Kimberly E McHugh; Peter Dean; G Paul Matherne
Journal:  World J Pediatr Congenit Heart Surg       Date:  2011-10-01

4.  Congenital heart disease in the general population: changing prevalence and age distribution.

Authors:  Ariane J Marelli; Andrew S Mackie; Raluca Ionescu-Ittu; Elham Rahme; Louise Pilote
Journal:  Circulation       Date:  2007-01-08       Impact factor: 29.690

5.  Outcomes of heart failure-related hospitalization in adults with congenital heart disease in the United States.

Authors:  Fred H Rodriguez; Douglas S Moodie; Dhaval R Parekh; Wayne J Franklin; David L S Morales; Farhan Zafar; Gerald J Adams; Richard A Friedman; Joseph W Rossano
Journal:  Congenit Heart Dis       Date:  2012-11-16       Impact factor: 2.007

6.  Mortality in adult congenital heart disease.

Authors:  Carianne L Verheugt; Cuno S P M Uiterwaal; Enno T van der Velde; Folkert J Meijboom; Petronella G Pieper; Arie P J van Dijk; Hubert W Vliegen; Diederick E Grobbee; Barbara J M Mulder
Journal:  Eur Heart J       Date:  2010-03-05       Impact factor: 29.983

7.  Specialized adult congenital heart disease care: the impact of policy on mortality.

Authors:  Darren Mylotte; Louise Pilote; Raluca Ionescu-Ittu; Michal Abrahamowicz; Paul Khairy; Judith Therrien; Andrew S Mackie; Ariane Marelli
Journal:  Circulation       Date:  2014-03-03       Impact factor: 29.690

8.  Trends in hospitalizations for adults with congenital heart disease in the U.S.

Authors:  Alexander R Opotowsky; Omar K Siddiqi; Gary D Webb
Journal:  J Am Coll Cardiol       Date:  2009-07-28       Impact factor: 24.094

9.  Hospital Resource Utilization for Common Noncardiac Diagnoses in Adult Survivors of Single Cardiac Ventricle.

Authors:  Michael D Seckeler; Tabitha G Moe; Ian D Thomas; Omar Meziab; Jennifer Andrews; Elissa Heller; Scott E Klewer
Journal:  Am J Cardiol       Date:  2015-09-10       Impact factor: 2.778

Review 10.  A review of the economics of adult congenital heart disease.

Authors:  Michael D Seckeler; Ian D Thomas; Jennifer Andrews; Keith Joiner; Scott E Klewer
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2016-02-02       Impact factor: 2.217

View more
  3 in total

Review 1.  Building an Adult Congenital Heart Program: Critical Components and Important Allies.

Authors:  Akanksha Thakkar; Stephanie Fuentes-Rojas; Eunice Karanja; Ebun Ebunlomo; Allison Millette; Christine H Lee; Y Serena Shen-Lin; Gary Monteiro; Thomas MacGillivray; C Huie Lin
Journal:  Curr Cardiol Rep       Date:  2018-10-11       Impact factor: 2.931

2.  Trends in Patient Characteristic, Cost, and Mortality Among Mechanically Ventilated Adult Patients With Congenital Heart Disease in the United States.

Authors:  Karen Ho; Idris Bare; Eric Sy; Jyoptal Singh; Alexander R Opotowsky; Payam Dehghani
Journal:  CJC Open       Date:  2021-10-02

3.  Clinical progress note: Noncardiac complications in adults with congenital heart disease.

Authors:  Angela M Quain; Aniruddha S Paranjpe; Michael R Joynt
Journal:  J Hosp Med       Date:  2022-06-29       Impact factor: 2.899

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.